Mergers and acquisitions highlights to 09:20 GMT

Mergers and acquisitions highlights to 09:20 GMT

	Published : Tue, 13 Mar 2007 10:37 By : Agencies Print this Story

2007-03-13 09:15:31

Mota Engil's Martifer affiliate delays planned IPO; wants to debut in June

LISBON (AFX) - Mota Engil SGPS' Martifer affiliate is delaying the planned

IPO for 25 pct of its share capital, originally targeted for March 22, and wants

to debut on the Portuguese stock market in June, Jornal de Negocios reported

citing Martifer chairman, Carlos Martins.

2007-03-13 09:09:44

Infineon reiterates it wants to sell majority stake in US-listed Qimonda

MUNICH (AFX) - Infineon Technolgies AG still intends to sell a majority

stake in its US-listed Qimonda AG memory chip unit, the company said in a set of

slides published on its website.

2007-03-13 09:07:44

Altadis says report of possible merger talks with Imperial Tobacco 'unfounded'

MADRID (AFX) - Altadis SA said a report in the Spanish press of a possible

friendly merger with Imperial Tobacco Group PLC to create an offensive against a

hostile takeover of the UK tobacco company by private equity group Kohlberg

Kravis Roberts & Co is 'unfounded'.

2007-03-13 09:07:14

Ranbaxy, Cipla bid 6 bln usd for Merck KGaA generics, Dr Reddy's drops out

NEW DELHI (AFX) - Indian generic drug companies Ranbaxy Laboratories and

Cipla said at a press conference that they have presented their offer for Merck

KGaA's generic drug operations, and the offer is valued at 6 bln usd.

2007-03-13 09:03:15

Tandberg TV FY restated net 82.9 usd vs initial 55.6 mln after tax credit boost

OSLO (AFX) - Norwegian group Tandberg Television ASA said it restated its

full year net profit at 82.9 usd mln compared with the 55.6 mln reported on Feb

8 due to a tax credit.

2007-03-13 09:02:51

Ranbaxy, Cipla bid 6 bln usd for Merck KGaA's generic ops, Dr Reddy's drops out

- Indian generic drug companies Ranbaxy Laboratories and Cipla said at a

press conference that they have presented their offer for Merck KGaA's generic

drug operations, and the offer is valued at 6 bln usd.